Q2 2015 13F Holders as of 6/30/2015
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
14.4M
-
Number of holders
-
134
-
Total 13F shares, excl. options
-
11.9M
-
Shares change
-
-133K
-
Total reported value, excl. options
-
$395M
-
Value change
-
-$15.2M
-
Put/Call ratio
-
0.72
-
Number of buys
-
68
-
Number of sells
-
-75
-
Price
-
$33.03
Significant Holders of Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) as of Q2 2015
171 filings reported holding ANIK - Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q2 2015.
Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) has 134 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11.9M shares
of 14.4M outstanding shares and own 82.84% of the company stock.
Largest 10 shareholders include THOMPSON SIEGEL & WALMSLEY LLC (1.05M shares), BlackRock Fund Advisors (876K shares), WELLINGTON MANAGEMENT GROUP LLP (856K shares), LOMBARDIA CAPITAL PARTNERS LLC (852K shares), DIMENSIONAL FUND ADVISORS LP (719K shares), BTIM Corp. (682K shares), VANGUARD GROUP INC (600K shares), BlackRock Institutional Trust Company, N.A. (498K shares), Portolan Capital Management, LLC (494K shares), and AMI ASSET MANAGEMENT CORP (361K shares).
This table shows the top 134 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.